Closely-held Zucara Therapeutics received an additional $2-million in funding from JDRF (Juvenile Diabetes Research Foundation) to support Zucara’s planned Phase 2a study of the effect of its ZT-01 on nocturnal...
Search results for - zucara
Zucara receives IND clearance for Phase 2 trial of ZT-01 for prevention of night-time hypoglycemia
The FDA has cleared Zucara Therapeutics’ IND application for a Phase 2a study of ZT-01 for the prevention of nocturnal hypoglycemia in patients with Type 1 Diabetes (T1D), with first patient dosing set in the third...
Zucara secures Phase 2 funding for hypoglycemia trial
Closely-held Zucara Therapeutics’ positive proof-of-concept data has enabled the company to secure continued funding for a Phase 2 clinical study of ZT-01 to prevent hypoglycemia in people with Type 1 diabetes, which is...
Zucara Therapeutics reports positive results from Phase 1b trial in T1D
Closely-held Zucara Therapeutics reported that its Phase 1b proof-of-concept trial demonstrated ZT-01’s ability to restore glucagon release in people with Type 1 diabetes. Data from 18 subjects that completed all three...
Zucara Therapeutics secures additional funding to develop ZT-01 for T2D
Closely-held Zucara Therapeutics received second grants from each of GlycoNet and Mitacs to support the development of ZT-01 for the treatment of insulin-induced hypoglycemia in people with Type 2 diabetes. “GlycoNet’s...
Zucara awaiting proof-of-concept data to prevent insulin-induced hypoglycemia in people with diabetes
Closely-held Zucara Therapeutics expects to release results in the second quarter of its Phase 1b proof-of-concept study with its once-daily drug candidate, ZT-01, to prevent insulin-induced hypoglycemia, or low blood...
Zucara Expands ZT-01 Development to Type 2 Diabetes
Closely-held Zucara Therapeutics is expanding the development of ZT-01, which is currently in a Phase 1 trial for the prevention of insulin-induced hypoglycemia in patients with Type 1 Diabetes...
Zucara doses first subject in Phase 1 trial of ZT-01
Closely-held Zucara Therapeutics dosed the first subject in its Phase 1 trial of ZT-01, a once-daily somatostatin inhibitor designed to prevent insulin-induced hypoglycemia. The first, single ascending dose portion...
Zucara Therapeutics in $21-million Series A funding led by Perceptive Xontogeny
Closely held Zucara Therapeutics closed a $21-million Series A financing led by the Perceptive Xontogeny Venture (PXV) Fund. Proceeds will be used for Phase 1 and Phase 2 clinical trials of ZT-01, Zucara’s first-in...
